Despite Medicare Coverage, Cancer Genomic Testing Still Low

Published Date: 31 Jul 2026

Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic tests. But uptake remains low.

Read Full News

Latest News

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Todays Updates

Diagnosis of Mass Confined to the Kidney: Is It RCC or TCC?

Ureteroscopy and histopathology should be considered as routine preoperative assessments

BRAF Inhibition in Pediatric Ameloblastoma of the Jaw

Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state

Todays Updates

Diagnosis of Mass Confined to the Kidney: Is It RCC or TCC?

Ureteroscopy and histopathology should be considered as routine preoperative assessments

BRAF Inhibition in Pediatric Ameloblastoma of the Jaw

Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state

Latest News

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

News All Time

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Recommended News For You

New target points to combination therapy for thwarting multidrug resistance in cancer treatment

Trial Challenges Indefinite Maintenance for Multiple Myeloma

'Sleep ALL night' program helps children with leukemia sleep better during treatment

Stem Cell Transplant Linked to Longer Survival in CMML

Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer

Researchers have determined that malignancy hibernation will be the next front in the fight against breast cancer.

UK Lawmakers Reject Bid to Legalise Assisted Dying

Recommended Articles For You

Unlocking the Potential of Plinabulin: A New Frontier in Cancer Treatment 

How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology 

Building Bridges between Heart and Cancer Care: A Comprehensive Guide to Cardio-Oncology Clinics 

Innovative Advances in Oncology for Specialists 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For incarcerated people, study shows gaps exist in quality of cancer care

2.

Video: How to treat kidney disease?

3.

FDA Expands Approval of Osimertinib in Lung Cancer

4.

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

5.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

1.

Immune Landscape Evolution in the Tumor Stromal Ecosystem

2.

Understanding Waldenstrom Macroglobulinemia - A Comprehensive Guide 

3.

Advancements in Squamous Cell Carcinoma Treatment: Decoding Survival Strategies and Molecular Pathways to Improve Cure Rates

4.

Quality of Life Following Organ Function Preserving Oncologic Innovation

5.

Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Expert Perspectives on Hematology

2.

Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

5.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot